- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02284230
The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure (LiRA2)
Glycaemic and Cardiovascular Efficacy of Liraglutide in Prediabetic Patients With End-stage Renal Disease
The present study will examine the effects of liraglutide treatment during 26 weeks on several cardiovascular risk factors in patients with prediabetes and end-stage renal disease (ESRD). The primary objective is to determine the efficacy of the treatment on glucose tolerance evaluated during a 3h 75g-oral glucose tolerance test (OGTT). Secondary objectives include various clinical and biochemical cardiovascular and safety parameters.
We hypothesise that treatment with liraglutide can improve glucose tolerance in prediabetic patients with ESRD by normalizing plasma glucose excursions during an OGTT and ameliorate other cardiovascular risk factors.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark, 2100
- Department of Nephrology, Rigshospitalet
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- End-stage renal disease treated with chronic maintenance dialysis (haemodialysis or peritoneal dialysis)
- Impaired glucose tolerance (2h plasma glucose ≥ 7,8 and < 11.1 mmol/l following a 75g-OGTT) and/or impaired fasting glucose (fasting plasma glucose ≥ 6.1 and < 7.0 mmol/l) evaluated at the screening visit
Exclusion Criteria:
- Diabetes mellitus type 1 or type 2 (diagnose according to WHO criteria)
- Chronic pancreatitis / previous acute pancreatitis
- Known or suspected hypersensitivity to trial product(s) or related products
- Treatment with oral glucocorticoids, calcineurin inhibitors or incretin-based therapy which in the Investigator's opinion could interfere with glucose or lipid metabolism 90 days prior to screening
- Cancer (except basal cell skin cancer or squamous cell skin cancer) or any other clinically significant disorder, which in the investigator's opinion could interfere with the results of the trial
- Clinical suspicion of cardiac disease currently investigated
- Cardiac disease defined as: decompensated heart failure (NYHA class III-IV) and/or diagnosis of unstable angina pectoris and/or myocardial infarction within the last 6 months
- Body mass index (BMI) <20 kg/m2 and/or >50 kg/m2
- Females of childbearing potential who are pregnant, breast-feeding, intend to become pregnant or are not using adequate contraceptive methods*
- Impaired liver function (transaminases > two times upper reference levels)
- The receipt of any investigational product 90 days prior to this trial
- Known or suspected abuse of alcohol or narcotics
- Screening calcitonin ≥ 50 ng/l
- Subjects with personal or family history of medullary thyroid carcinoma or a personal history of multiple endocrine neoplasia type 2
Lawfully detained, institutionalised and patients who are unable to give informed consent due to physical or mental conditions will not be included.
* Intrauterine devices and hormonal contraceptives (oral pills, patches, implants, vaginal rings, and injections) are considered as adequate contraceptives. Females of childbearing potential must use one of these contraceptives throughout the entire study plus 1 week after last injection with study medication. Surgical sterile (by bilateral vasectomy, tubectomy, hysterectomy or oophorectomy) or postmenopausal (defined as amenorrheic for at least one year) female participants are not considered as having a childbearing potential and are not required to use contraception.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Liraglutide treatment
Subcutaneous, once daily injection of liraglutide, individually dosed up to 1.8 mg/day.
|
Other Names:
|
Placebo Comparator: Placebo treatment
Subcutaneous, once daily injection of placebo, individually dosed up to 1.8 mg/day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma glucose during oral glucose tolerance test at week 26
Time Frame: The trial visit of week 26
|
Difference between the two treatment arms in plasma glucose concentrations during a 3h 75g-OGTT on the trial visit of week 26
|
The trial visit of week 26
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hypoglycemic incidents
Time Frame: From the randomisation to trial visit of week 26
|
Total hypoglycemic episodes during intervention
|
From the randomisation to trial visit of week 26
|
Fasting values of glucometabolic hormones
Time Frame: The trial visit of week 26
|
Fasting plasma glucose, proinsulin, insulin and glucagon
|
The trial visit of week 26
|
Insulin resistance
Time Frame: The trial visit of week 26
|
Insulin resistance evaluated by homeostasis model assessment (HOMA)
|
The trial visit of week 26
|
Beta cell function
Time Frame: The trial visit of week 26
|
Beta-cell function evaluated by HOMA
|
The trial visit of week 26
|
Change in glycemic state
Time Frame: The trial visit of week 26
|
Change in glycemic state following oral glucose tolerance test (normal glucose tolerance (NGT, fasting plasma glucose < 6.1 mmol/l and 2h plasma glucose < 7.8 mmol/l), impaired fasting glucose (IFG, fasting plasma glucose ≥ 6.1 and < 7.0 mmol/l), impaired glucose tolerance (IGT, 2h plasma glucose ≥ 7,8 and < 11.1 mmol/l) and diabetes mellitus (DM, fasting plasma glucose ≥ 7 mmol/l or 2h plasma glucose ≥ 11.1 mmol/l))
|
The trial visit of week 26
|
Blood pressure
Time Frame: The trial visit of week 26
|
Blood Pressure
|
The trial visit of week 26
|
Pulse
Time Frame: The trial visit of week 26
|
Resting pulse
|
The trial visit of week 26
|
Weight
Time Frame: The trial visit of week 26
|
Weight
|
The trial visit of week 26
|
Body composition
Time Frame: The trial visit of week 26
|
Body composition by dual energy x-ray absorptiometry (DXA) scan
|
The trial visit of week 26
|
Cardiac function and perfusion
Time Frame: The trial visit of week 26
|
Cardiac function and perfusion evaluated by Rb-PET/CT scan
|
The trial visit of week 26
|
Cardiac autonomic function
Time Frame: The trial visit of week 26
|
Cardiac autonomic function evaluated by heart rate variability
|
The trial visit of week 26
|
Arterial stiffness
Time Frame: The trial visit of week 26
|
Arterial stiffness evaluated by Augmentation index from Pulse wave analysis
|
The trial visit of week 26
|
Cardiovascular and endothelial risk markers
Time Frame: The trial visit of week 26
|
Cardiovascular and endothelial risk markers (troponin T, troponin I, creatine kinase-MB, high-sensitivity C-reactive protein (hsCRP), plasminogen activator inhibitor 1 (PAI-1), Tissue plasminogen activator (tPA), urat, von Willebrand factor (vWF), vascular endothelial cell adhesion molecule (VCAM), intercellular adhesion molecule (ICAM), TNFalpha, proBNP, E-selectin and asymmetric dimethylarginine)
|
The trial visit of week 26
|
Prothrombotic state
Time Frame: The trial visit of week 26
|
Prothrombotic state (fibrinogen, activated partial thromboplastin time (APTT) and thromboelastography (TEG))
|
The trial visit of week 26
|
Lipid profile
Time Frame: The trial visit of week 26
|
Lipid profile
|
The trial visit of week 26
|
Plasma liraglutide
Time Frame: The trial visit of week 26
|
Plasma liraglutide
|
The trial visit of week 26
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bo Feldt-Rasmussen, Prof,MD,DMSc, Rigshospitalet, Denmark
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Kidney Diseases
- Urologic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Renal Insufficiency, Chronic
- Kidney Failure, Chronic
- Prediabetic State
- Renal Insufficiency
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Incretins
- Liraglutide
Other Study ID Numbers
- U1111-1149-7801
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Failure, Chronic
-
Centre Hospitalier Universitaire DijonTerminatedEnd-stage Chronic Kidney FailureFrance
-
Angiodynamics, Inc.TerminatedChronic Kidney Disease | Acute Kidney Injury | Acute Renal Failure | Renal Failure Chronic Contrast InducedUnited States
-
Texas A&M UniversityWithdrawnChronic Kidney FailureUnited States
-
Baxter Healthcare CorporationRecruitingAcute Kidney Failure | Chronic Kidney FailureChina
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
Hopital Jean MinjozUnknownCardiac Surgical Procedures | Preoperative KIDNEY FAILURE, CHRONIC | Postoperative KIDNEY FAILURE, ACUTEFrance
-
Nantes University HospitalNot yet recruiting
-
Ozge AKBABAAtaturk UniversityCompletedChronic Kidney FailureTurkey
-
Chinese PLA General HospitalCompletedKidney Failure,ChronicChina
-
Fatma Alzahraa Mohamed Ibrahim Hassan HaggagUnknown
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States